Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peyman Hadji

Showing results (101-110 of 171) with videos related to

Pageof 18
Sort By:
The Journal of Clinical Endocrinology and Metabolism|May 27, 2020
Osteoporosis in Premenopausal Women: A Clinical Narrative Review by the ECTS and the IOFJessica Pepe, Jean-Jacques Body, Peyman Hadji, et al.
Breast (Edinburgh, Scotland)|August 29, 2009
Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancerRowan Chlebowski, Jack Cuzick, Dereck Amakye, et al.
Geburtshilfe Und Frauenheilkunde|September 27, 2021
Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg DrospirenoneThomas Römer, Johannes Bitzer, Christian Egarter, et al.
Breast Care (Basel, Switzerland)|January 15, 2014
Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast CancerNadia Harbeck, Maria Blettner, Peyman Hadji, et al.
Geburtshilfe Und Frauenheilkunde|December 13, 2022
Correction: Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg DrospirenoneThomas Römer, Johannes Bitzer, Christian Egarter, et al.
The Journal of Clinical Endocrinology and Metabolism|December 28, 2007
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosisSteven Boonen, Fernando Marin, Barbara Obermayer-Pietsch, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 29, 2008
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatmentBarbara M Obermayer-Pietsch, Fernando Marin, Eugene V McCloskey, et al.
Kardiologia Polska|February 29, 2008
[Management of cardiovascular risk in the peri-menopausal woman--a consensus statement of European cardiologists and gynaecologists]Peter Collins, Guiseppe Rosano, Catherine Casey, et al.
European Heart Journal|July 24, 2007
Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologistsPeter Collins, Guiseppe Rosano, Catherine Casey, et al.
Journal of Cancer Research and Clinical Oncology|December 21, 2010
The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studiesPeyman Hadji, Lina Asmar, Johanna G H van Nes, et al.
Pageof 18

Showing results (101-110 of 171) with videos related to

Sort By:
Pageof 18
The Journal of Clinical Endocrinology and Metabolism|May 27, 2020
Osteoporosis in Premenopausal Women: A Clinical Narrative Review by the ECTS and the IOFJessica Pepe, Jean-Jacques Body, Peyman Hadji, et al.
Breast (Edinburgh, Scotland)|August 29, 2009
Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancerRowan Chlebowski, Jack Cuzick, Dereck Amakye, et al.
Geburtshilfe Und Frauenheilkunde|September 27, 2021
Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg DrospirenoneThomas Römer, Johannes Bitzer, Christian Egarter, et al.
Breast Care (Basel, Switzerland)|January 15, 2014
Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast CancerNadia Harbeck, Maria Blettner, Peyman Hadji, et al.
Geburtshilfe Und Frauenheilkunde|December 13, 2022
Correction: Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg DrospirenoneThomas Römer, Johannes Bitzer, Christian Egarter, et al.
The Journal of Clinical Endocrinology and Metabolism|December 28, 2007
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosisSteven Boonen, Fernando Marin, Barbara Obermayer-Pietsch, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 29, 2008
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatmentBarbara M Obermayer-Pietsch, Fernando Marin, Eugene V McCloskey, et al.
Kardiologia Polska|February 29, 2008
[Management of cardiovascular risk in the peri-menopausal woman--a consensus statement of European cardiologists and gynaecologists]Peter Collins, Guiseppe Rosano, Catherine Casey, et al.
European Heart Journal|July 24, 2007
Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologistsPeter Collins, Guiseppe Rosano, Catherine Casey, et al.
Journal of Cancer Research and Clinical Oncology|December 21, 2010
The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studiesPeyman Hadji, Lina Asmar, Johanna G H van Nes, et al.
Pageof 18